Increased survival of infants born preterm, especially those born extremely preterm (< 28
weeks' gestation), has meant that more are reaching later childhood and adulthood. As …

Background Preterm birth-related complications are the leading cause of death in newborns
and children under 5. Health outcomes of preterm newborns can be improved with …

Despite improvements in perinatal care, preterm birth still occurs regularly and the
associated brain injury and adverse neurological outcomes remain a persistent challenge …

Antenatal administration of magnesium sulfate is an important part of the neuroprotective
strategy for preterm infants. Strong evidence from five randomized controlled trials and five …

Prematurity remains a proximate cause of infant morbidity and mortality. 1 Despite extensive
years of research and investment, limited gains have been made in preventing preterm birth …

Background Evidence supports magnesium sulphate (MgSO4) for women at risk of imminent
birth at< 32–34 weeks to reduce the likelihood of cerebral palsy in the child. MAGnesium …

Purpose Preterm birth (PTB) can be categorised according to aetiology into: spontaneous
preterm labour (SPL), preterm prelabour rupture of membranes (PPROM), and iatrogenic …

Background Magnesium sulfate is an accepted intervention for fetal neuroprotection. There
are some perceived differences in the international recommendations on the use …

Background Takotsubo cardiomyopathy is rare in pregnancy and is characterized by left
ventricular dysfunction with apical ballooning. This transient cardiac dysfunction may affect …

Background Clinical practice guidelines recommend the use of antenatal magnesium
sulphate for fetal neuroprotection before preterm birth at< 30 weeks' gestation. Aims This …